GlobeNewswire

Does Your Mask/Respirator Filter Live Viruses?

Share

For the First Time Scientific Data From a Certified Canadian Laboratory Answers This Fundamental Question.

MIRABEL, Quebec, Canada, March 23, 2021 (GLOBE NEWSWIRE) -- i3 Biomedical inc., a medical device corporation, releases today the comparative results of Live viruses Filtration performances of numerous Medical Face masks and Respirators in the tables included. For a comprehensive understanding, the results are rendered in the form of number of viruses inhaled per Minute per Mask/Respirator based on the average volume of air of 7 liter per minute required by humans. The scientific data is the result of advanced testing executed by GAP EnviroMicrobial Services Ltd., an independent Canadian ISO certified laboratory.

All Procedure masks, Medical Masks and Respirators (further referred to as “Masks”) following the European and/or American regulatory standards are not required to be tested against live viruses, but only against either a solid particle (example: salt particles) or against bacteria (which are approximately 100 times bigger in size than viruses).

The only regulated standards currently used in the Americas and in Europe that include testing the assessment of the filtration performances of microbes are respectively the North American ASTM 2100 and the European EN14683 Bacterial Filtration Efficiency (BFE). While it is not a government requirement, the substitution of the Bacteria for a Live Virus to test Viral Filtration Efficiency (VFE) is accepted. These standardized testing protocols require a concentration of 10^5 viruses per liter of air for only a 2-minute testing time, hence providing the filtration performance of “Masks” in use for 2 minutes only. GAP EnviroMicrobial Services Ltd. was mandated to test the (VFE) following the same protocols but for a testing time of 30 minutes at the NIOSH1 recommended air speed of 85 LPM, on various masks (Procedure masks, Surgical/Medical masks ASTM Level 3, CE Type IIR, KN 95 masks, N95 masks and FFP2 masks).  The above-mentioned testing is done on the filter materials only of the masks as per protocol requirements.

For reference, a single cough from an infected subject can release an average of 4,914,600 aerosolized viral particles2. Find the answer to: Does your mask/respirator filter live Viruses in the Tables included.

For more information on the TrioMed Active face masks, visit www.triomed.com or send an email to triomed@triomed.com

About i3 BioMedical Inc: i3 BioMedical is a Canadian medical device corporation, focused on the development and manufacturing of novel antimicrobial products incorporating the TrioMed Active Technology.

About GAP EnviroMicrobial Services Ltd.: GAP EnviroMicrobial Services Ltd. (GAP), established in 1996, is ISO/IEC 17025:2005 compliant with accreditation by the Canadian Association for Laboratory Accreditation (CALA), CALA accreditation is recognized by almost 60 accrediting bodies in 40 countries around the world.

1 National Institute for Occupational Safety and Health 
2 Lee, J., Yoo, D., Ryu, S., Ham, S., Lee, K., Yeo, M., Min, K. and Yoon, C. (2019). Quantity, Size Distribution, and Characteristics of Cough-generated Aerosol Produced by Patients with an Upper Respiratory Tract Infection. Aerosol Air Qual. Res. 19: 840-853. https://doi.org/10.4209/aaqr.2018.01.0031


Photos: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/6b7816c8-e759-424c-883e-08620c20283e

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca1644fd-d4c7-464d-b277-e83e986707b7

https://www.globenewswire.com/NewsRoom/AttachmentNg/8ce6b02b-2bbf-4d04-a8a3-2d37eaa0d15f


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

REC Silicon - Notice of Annual General Meeting20.4.2021 15:12:01 CEST | Press release

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Lysaker, Norway - April 20, 2021: Notice is hereby given that the Annual General Meeting of REC Silicon ASA (REC) will be held at the offices of Schjødt, Ruseløkkveien 14, Oslo, Norway on May 11, 2021 at 4.00 pm CET. Please find attached Notice of the General Meeting and the Recommendation of the Nomination Committee. All documents are available at https://www.recsilicon.com/investors/agm/ Due to the extraordinary situation with Covid-19, and in light of prevailing travel and meeting recommendations and restrictions, the Board urges shareholders to vote through submission of proxy forms prior to the meeting and not attend the meeting in person. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: james.may@recsilicon.com Nils O. Kjerstad, IR Contact Phone: +47 9135 6659 Email: nils.kjerstad@crux.no About REC

Årsredovisning 2020 är nu publicerad20.4.2021 15:00:00 CEST | Pressemelding

2021-04-20 PRESSRELEASE Årsredovisning 2020är nu publicerad Arcoma publicerar idag sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.arcoma.se/about-us/investors. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Adviser är Erik Penser Bank (tel: 08-4638300, e-mail: certifiedadviser@penser.se) För mer information om bolaget besök www.arcoma.se För ytterligare information, vänligen kontakta: Arcomas VD Sanna Rydbe

Skyharbour’s Partner Company Valor Completes Airborne Survey at Hook Lake Uranium Project, Saskatchewan20.4.2021 14:00:00 CEST | Press release

VANCOUVER, British Columbia, April 20, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that partner company Valor Resources Limited (“Valor”) entered into a contract with Precision GeoSurveys Inc. through TerraLogic Exploration Inc. (“TerraLogic”), the Company’s geological consultants, to undertake a detailed airborne survey over the Hook Lake Project (previously North Falcon Point). The survey commenced in early April 2021 and is now complete. TerraLogic designed the low-level airborne magnetic and VLF-EM survey to cover the entire Hook Lake claim area, using a fixed-wing aircraft, at 75m line-spacing totaling 5,100 line-km. Final data processing, data interpretation, target selection and recommendations for follow-up ground-based exploration and drilling programs will also be handled by TerraLogic. This process is expected to take approximately six weeks, followed immediately by the recommended fi

Acarix publicerar årsredovisningen för 202020.4.2021 13:00:00 CEST | Pressemelding

Pressmeddelande Malmö, 20 april 2021 Acarix publicerar årsredovisningen för 2020 Idag, tisdagen den 20 april, publicerar Acarix sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.acarix.com. Årsredovisningen finns även bifogad i pressreleasen. För mer information, vänligen kontakta: Per Persson, vd, e-mail: per.persson@acarix.com, telefon: +46 73 600 59 90 Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande vid den tidpunkt som anges av företagets nyhetsdistributör, GlobeNewswire. Om Acarix Acarix grundades 2009 och är noterat på Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix CADScor®System använder en avancerad sensor som placeras på huden ovanför hjärtat för att lyssna på ljudet av hjärtkontraktion och turbulent flöde. Det har utformats för att vara ett allt-i-ett-system i den meningen att signalen från hjärtat spelas in, bearbetas och visas som en patientspecifik s k CAD-score på skärmen. Presentation av mätresul

Acarix publishes the annual report for 202020.4.2021 13:00:00 CEST | Press release

Press release Malmö, Sweden, April 20, 2021 Acarix publishes the annual report for 2020 Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release. For further information, please contact: Per Persson, CEO, E-mail: per.persson@acarix.com, Phone: +46 73 600 59 90 The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire. About Acarix: Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the devi

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex20.4.2021 12:30:00 CEST | Press release

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3– LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe. “This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is

Fingerprint Cards AB: invitation to the first quarter 2021 results presentation20.4.2021 11:30:00 CEST | Press release

Fingerprint Cards AB (Fingerprints™) will host a telephone conference and webcast presentation of its first quarter 2021 results, on April21, 2021 at 09:00 CEST. Fingerprints’ CEO Christian Fredrikson will present the report together with CFO Per Sundqvist in a combined webcast and telephone conference. The presentation will be held in English. Time: Wednesday, April 21, 2021 at 09:00 am CEST. Location: combined webcast and telephone conference. The report is available at https://www.fingerprints.com/ The webcast and the presentation material can be accessed through https://edge.media-server.com/mmc/p/5dpwm66j where it is also possible to ask questions. For media and analysts: The telephone conference dial-in is +44 (0) 2071 928000 (international participants) or 08-506 921 80 (Swedish participants). Please state conference ID 9862978. About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and se